She is board certified by the American Board of Genetics and Genomics as a PhD Medical Geneticist. Her laboratory studies the role of genetic variants in modifying disease risk of a variety of hereditary and sporadic cancers using in vitro, in vivo and population-based approaches. Current studies are focused on new means to classify variants of uncertain clinical significance in hereditary breast cancer genes, the integration of low-penetrance genetic variants to modify risk prediction into the clinic, and the identification of driver mutations and circulating microRNAs in metastatic cutaneous squamous cell carcinomas.